Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 108Breast Neoplasms 72Carcinoma, Non-Small-Cell Lung 38Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 14Esophageal Squamous Cell Carcinoma 14Neoplasms 12Head and Neck Neoplasms 11Lung Neoplasms 10Stomach Neoplasms 9Gallbladder Neoplasms 8Cholangiocarcinoma 8Adenocarcinoma 8Melanoma 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Sarcoma 6Ovarian Neoplasms 5Inflammatory Breast Neoplasms 5Small Cell Lung Carcinoma 4Recurrence 4Pancreatic Adenocarcinoma 4Carcinoma, Ductal, Breast 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Tongue Neoplasms 3Thymoma 3Pancreatic Diseases 3Nasopharyngeal Carcinoma 3

Interventions

apatinib 2Pemetrexed 2pembrolizumab 1lenvatinib 1Paclitaxel 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Non-squamous Non-small-cell Lung Cancer × 130-nm albumin-bound paclitaxel × Clear all
NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Peking University First Hospital

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡